AMPK activation: a therapeutic target for type 2 diabetes?

Type 2 diabetes (T2D) is a metabolic disease characterized by insulin resistance, β-cell dysfunction, and elevated hepatic glucose output. Over 350 million people worldwide have T2D, and the International Diabetes Federation projects that this number will increase to nearly 600 million by 2035. Ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Coughlan, Kimberly A, Valentine, Rudy J, Ruderman, Neil B, Saha, Asish K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4075959/
https://www.ncbi.nlm.nih.gov/pubmed/25018645
http://dx.doi.org/10.2147/DMSO.S43731

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4075959/
https://www.ncbi.nlm.nih.gov/pubmed/25018645
http://dx.doi.org/10.2147/DMSO.S43731

Ejemplares similares